MAPT and Alzheimer disease: PC 3 was correlated with the CSF biomarkers generally used for biologically defining Alzheimer’s disease (Aβ42, P-tau181, t-tau, Aβ42/40, p-tau/Aβ42) but also with the cognitive performance of the patients (MMSE, MoCA, KOD, RCF, RAVLT) and MRI measures (WM hypointensities, hippocampal volume, cortical thickness, Alzheimer’s disease signature thickness; Fig. 4A, Table 3).